CY1121950T1 - Νεα αντισωματα εναντι φωσφορυλχολινης - Google Patents

Νεα αντισωματα εναντι φωσφορυλχολινης

Info

Publication number
CY1121950T1
CY1121950T1 CY20191100683T CY191100683T CY1121950T1 CY 1121950 T1 CY1121950 T1 CY 1121950T1 CY 20191100683 T CY20191100683 T CY 20191100683T CY 191100683 T CY191100683 T CY 191100683T CY 1121950 T1 CY1121950 T1 CY 1121950T1
Authority
CY
Cyprus
Prior art keywords
sequence
amino acid
seq
acid sequence
identity
Prior art date
Application number
CY20191100683T
Other languages
Greek (el)
English (en)
Inventor
Knut Pettersson
Ola Camber
Dan SEXTON
Andrew E NIXON
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of CY1121950T1 publication Critical patent/CY1121950T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
CY20191100683T 2011-08-09 2019-06-28 Νεα αντισωματα εναντι φωσφορυλχολινης CY1121950T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161521593P 2011-08-09 2011-08-09
PCT/EP2012/065505 WO2013020995A1 (en) 2011-08-09 2012-08-08 New antibodies against phosphorylcholine

Publications (1)

Publication Number Publication Date
CY1121950T1 true CY1121950T1 (el) 2020-10-14

Family

ID=46679261

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100683T CY1121950T1 (el) 2011-08-09 2019-06-28 Νεα αντισωματα εναντι φωσφορυλχολινης

Country Status (28)

Country Link
US (3) US9803028B2 (enExample)
EP (1) EP2742068B1 (enExample)
JP (1) JP6277125B2 (enExample)
KR (1) KR101947758B1 (enExample)
CN (1) CN104039832B (enExample)
AR (1) AR087485A1 (enExample)
AU (1) AU2012293646B2 (enExample)
BR (1) BR112014002929A8 (enExample)
CA (1) CA2843921A1 (enExample)
CY (1) CY1121950T1 (enExample)
DK (1) DK2742068T3 (enExample)
ES (1) ES2732838T3 (enExample)
HK (1) HK1200852A1 (enExample)
HR (1) HRP20190988T1 (enExample)
HU (1) HUE045163T2 (enExample)
LT (1) LT2742068T (enExample)
MX (1) MX364425B (enExample)
PL (1) PL2742068T3 (enExample)
PT (1) PT2742068T (enExample)
RS (1) RS58986B1 (enExample)
RU (1) RU2654584C2 (enExample)
SG (1) SG2014009344A (enExample)
SI (1) SI2742068T1 (enExample)
SM (1) SMT201900366T1 (enExample)
TR (1) TR201909072T4 (enExample)
TW (1) TWI707873B (enExample)
WO (1) WO2013020995A1 (enExample)
ZA (1) ZA201400665B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
SI2742068T1 (sl) * 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova protitelesa proti fosforilholinu
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US20180066262A1 (en) 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
EP3328873B1 (en) 2015-07-28 2025-09-17 Caris Science, Inc. Targeted oligonucleotides
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3751182T2 (de) 1986-08-06 1995-10-26 Scripps Clinic Res Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
WO1990012632A1 (en) 1989-04-19 1990-11-01 The United States Of America, Represented By The Secretary, United States Department Of Commerce Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
EP0562020A4 (en) 1990-12-10 1993-11-18 Alving, Carl L. A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
RU2014609C1 (ru) * 1991-06-06 1994-06-15 Московский институт тонкой химической технологии им.М.В.Ломоносова Способ определения белков, специфичных к фосфорилхолину
EP0631624A1 (en) 1992-03-03 1995-01-04 The Rockefeller University Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
AU6268894A (en) 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
ES2205853T3 (es) 1998-07-03 2004-05-01 Athera Biotechnologies Ab Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz.
JP2003513027A (ja) 1999-10-26 2003-04-08 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア アテローム性動脈硬化症の診断、結像、治療用の薬剤及びその方法
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
AU2001259730A1 (en) 2000-05-12 2001-11-26 The Regents Of The University Of California Standardized oxidized ldl assay
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
CN1968965B (zh) 2004-04-15 2015-12-16 阿瑟拉生物技术公司 磷酸胆碱偶联物和相应抗体
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
US20110206679A1 (en) * 2008-07-07 2011-08-25 Athera Biotechnologies Ab New Therapeutic and Diagnostic Methods for Alzheimer's Disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
SI2742068T1 (sl) * 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova protitelesa proti fosforilholinu
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates

Also Published As

Publication number Publication date
MX2014001313A (es) 2014-07-28
PL2742068T3 (pl) 2020-01-31
LT2742068T (lt) 2019-07-10
US20140178410A1 (en) 2014-06-26
WO2013020995A1 (en) 2013-02-14
JP2014525233A (ja) 2014-09-29
CN104039832A (zh) 2014-09-10
AU2012293646B2 (en) 2017-08-31
SI2742068T1 (sl) 2019-08-30
HK1200852A1 (en) 2015-08-14
US20210238311A1 (en) 2021-08-05
US9803028B2 (en) 2017-10-31
HRP20190988T1 (hr) 2019-09-20
CN104039832B (zh) 2021-02-12
ZA201400665B (en) 2019-08-28
TWI707873B (zh) 2020-10-21
SMT201900366T1 (it) 2019-07-11
PT2742068T (pt) 2019-07-08
DK2742068T3 (da) 2019-06-11
ES2732838T3 (es) 2019-11-26
EP2742068B1 (en) 2019-04-03
HUE045163T2 (hu) 2019-12-30
AR087485A1 (es) 2014-03-26
AU2012293646A1 (en) 2014-02-20
TW201321415A (zh) 2013-06-01
SG2014009344A (en) 2014-07-30
AU2012293646A8 (en) 2014-03-06
RU2014108815A (ru) 2015-09-20
BR112014002929A8 (pt) 2021-09-28
KR101947758B1 (ko) 2019-02-14
KR20140068948A (ko) 2014-06-09
MX364425B (es) 2019-04-25
BR112014002929A2 (pt) 2017-03-28
US20180086848A1 (en) 2018-03-29
EP2742068A1 (en) 2014-06-18
TR201909072T4 (tr) 2019-08-21
RU2654584C2 (ru) 2018-05-21
JP6277125B2 (ja) 2018-02-07
RS58986B1 (sr) 2019-08-30
CA2843921A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
CY1121950T1 (el) Νεα αντισωματα εναντι φωσφορυλχολινης
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CY1121158T1 (el) Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης
NZ626269A (en) Anti-phf-tau antibodies and their uses
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
MY200988A (en) CD3 Binding Antibodies
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ726258A (en) Antibodies and uses thereof to detect folate receptor 1
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
CY1121249T1 (el) Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
NZ712765A (en) Antibodies that bind csf1r
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
PE20142322A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
JP2016530223A5 (enExample)
JP2017529324A5 (enExample)
EA201100160A1 (ru) Терапевтическое применение специфического лиганда при заболеваниях, связанных с msrv
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use